Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates
October 28, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
October 21, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress
October 20, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatmentsDemonstrated lipid nanoparticle-based delivery as a...
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
October 13, 2021 07:01 ET
|
Intellia Therapeutics, Inc.
Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise Intellia will grant SparingVision exclusive rights to its...
Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual Congress
October 12, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
First data highlighting proprietary allogeneic cell engineering platform designed to overcome immune rejection for the development of therapeutic candidates to treat a variety of cancer and autoimmune...
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
October 06, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
NTLA-2002 is the first single-dose genome editing therapeutic candidate designed to prevent attacks in people living with HAE to enter clinical studyNTLA-2002 is Intellia’s second in vivo CRISPR...
Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference
September 27, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
September 16, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering process for the treatment of cancer to enter clinical studyNTLA-5001 targets Wilms’ Tumor 1 (WT1), an...
Intellia Therapeutics to Present at September Healthcare Investor Conferences
August 31, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
August 05, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
Established proof of concept for the Company’s modular in vivo delivery platform with first-ever clinical data from systemically administered CRISPR genome editing candidate in humansInterim Phase 1...